دورية أكاديمية
Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.
| العنوان: | Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation. |
|---|---|
| المؤلفون: | Nakamae H; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Jun 06; Vol. 15, pp. 1403936. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*/adverse effects , Cyclophosphamide*/therapeutic use , Graft vs Host Disease*/prevention & control , Graft vs Host Disease*/etiology , Graft vs Tumor Effect*/immunology , Transplantation, Homologous*, Humans ; Immunosuppressive Agents/therapeutic use ; Animals |
| مستخلص: | Post-transplant cyclophosphamide (PTCy) is becoming the standard prophylaxis for graft-versus-host disease (GVHD) in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) and in HLA-matched allo-HCT. Immune reconstitution in the post-transplant setting may influence the graft-versus-tumor (GVT) effect because PTCy has a profound effect on T cell and natural killer cell functions and their reconstitution after allo-HCT. However, many recent studies have shown that the incidence of relapse after allo-HCT with PTCy is comparable to that after conventional allo-HCT. To further improve the outcomes, it is critical to establish a strategy to maintain or effectively induce the GVT effect when using PTCy as a platform for GVHD prophylaxis. However, there is a paucity of studies focusing on the GVT effect in allo-HCT with PTCy. Therefore, focusing on this issue may lead to the establishment of more appropriate strategies to improve transplantation outcomes without exacerbating GVHD, including novel therapies involving cell modification. Competing Interests: HN received research funding from Astellas Pharma Inc., Alexion Pharmaceuticals, Novartis Pharma K.K., Bristol-Myers Squibb, Takeda Pharmaceutical Co., Ltd., and Meiji Seika Pharma; and honoraria from Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb, Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Daiichi Sankyo, Chugai Pharmaceutical Co., Ltd., and Sanofi outside of this current work. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Nakamae.) |
| References: | Bone Marrow Transplant. 2020 Jan;55(1):12-24. (PMID: 30833742) Blood. 2022 Mar 10;139(10):1452-1468. (PMID: 34724567) Transplant Cell Ther. 2022 Aug;28(8):500.e1-500.e10. (PMID: 35662592) Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. (PMID: 32438042) Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42. (PMID: 19961944) Blood Rev. 2023 Nov;62:101078. (PMID: 37031067) Sci Immunol. 2021 Apr 23;6(58):. (PMID: 33893172) Transplant Cell Ther. 2023 Jun;29(6):377.e1-377.e7. (PMID: 36990221) Front Immunol. 2019 Nov 29;10:2668. (PMID: 31849930) Br J Haematol. 2024 Mar;204(3):959-966. (PMID: 38037468) Biol Blood Marrow Transplant. 2020 Feb;26(2):230-241. (PMID: 31586477) Transplant Cell Ther. 2021 Sep;27(9):782.e1-782.e7. (PMID: 34146733) Biol Blood Marrow Transplant. 2020 Apr;26(4):723-733. (PMID: 31899360) Oncotarget. 2017 Jun 29;8(38):63574-63586. (PMID: 28969012) Blood. 2018 Jan 11;131(2):247-262. (PMID: 28986344) Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10896-901. (PMID: 12960383) J Clin Med. 2021 Jun 27;10(13):. (PMID: 34199028) Cell Transplant. 2022 Jan-Dec;31:9636897221112098. (PMID: 35906755) Transplant Cell Ther. 2021 Nov;27(11):940-948. (PMID: 34329754) Bone Marrow Transplant. 2021 Jul;56(7):1683-1690. (PMID: 33658647) Acta Haematol. 2024 Mar 1;:. (PMID: 38432202) Trends Immunol. 2022 May;43(5):355-365. (PMID: 35370095) Leuk Res. 2017 Jun;57:60-64. (PMID: 28292719) Bone Marrow Transplant. 2023 Apr;58(4):386-392. (PMID: 36585459) J Hematol Oncol. 2020 May 6;13(1):46. (PMID: 32375860) Transplant Cell Ther. 2022 Sep;28(9):601.e1-601.e8. (PMID: 35788088) Blood Adv. 2023 Apr 25;7(8):1594-1603. (PMID: 36630564) Exp Hematol. 2015 Nov;43(11):921-929.e1. (PMID: 26284307) Front Immunol. 2023 Mar 20;14:1082727. (PMID: 37020562) Blood Adv. 2024 May 28;8(10):2332-2341. (PMID: 38429091) Front Immunol. 2022 Oct 13;13:1033871. (PMID: 36311784) Blood Adv. 2020 Oct 27;4(20):5311-5321. (PMID: 33108457) JCI Insight. 2021 Nov 22;6(22):. (PMID: 34637399) Bone Marrow Transplant. 2019 Aug;54(Suppl 2):708-712. (PMID: 31431716) Blood Adv. 2020 Aug 25;4(16):3900-3912. (PMID: 32813875) J Hematol Oncol. 2023 Mar 18;16(1):25. (PMID: 36934271) Crit Rev Oncol Hematol. 2019 Jan;133:120-128. (PMID: 30661648) Transplant Cell Ther. 2021 Nov;27(11):928.e1-928.e7. (PMID: 34274491) JAMA Oncol. 2019 Dec 1;5(12):1739-1748. (PMID: 31621796) Blood. 2006 Apr 1;107(7):2984-92. (PMID: 16317094) Transplant Cell Ther. 2021 Dec;27(12):1003.e1-1003.e13. (PMID: 34537419) Bone Marrow Transplant. 2017 May;52(5):797. (PMID: 28465624) Biol Blood Marrow Transplant. 2019 Dec;25(12):2422-2430. (PMID: 31386903) Sci Transl Med. 2013 Nov 13;5(211):211ra157. (PMID: 24225944) Exp Hematol. 2023 Jul;123:56-65. (PMID: 37098360) Best Pract Res Clin Haematol. 2011 Sep;24(3):359-68. (PMID: 21925089) J Immunol. 2020 Sep 1;205(5):1441-1448. (PMID: 32747504) Biol Blood Marrow Transplant. 2018 Jun;24(6):1232-1236. (PMID: 28918304) Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. (PMID: 29452245) Blood. 2024 Jun 13;143(24):2534-2543. (PMID: 38657278) J Hematol Oncol. 2018 Mar 15;11(1):40. (PMID: 29544522) Blood Adv. 2021 Jan 26;5(2):352-364. (PMID: 33496734) Bone Marrow Transplant. 2022 Aug;57(8):1260-1268. (PMID: 35562547) J Hematol Oncol. 2022 May 19;15(1):64. (PMID: 35590334) Biol Blood Marrow Transplant. 2019 Sep;25(9):1810-1817. (PMID: 31128326) Biol Blood Marrow Transplant. 2011 Feb;17(2):205-13. (PMID: 20736080) Bone Marrow Transplant. 2022 Dec;57(12):1781-1787. (PMID: 36097040) Haematologica. 2017 Nov;102(11):1810-1822. (PMID: 28883081) Bone Marrow Transplant. 2016 Dec;51(12):1599-1601. (PMID: 27526284) Curr Opin Hematol. 2010 Nov;17(6):493-9. (PMID: 20827187) Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. (PMID: 29055682) Blood Adv. 2018 Feb 13;2(3):299-307. (PMID: 29440002) Am J Hematol. 2024 Jan;99(1):38-47. (PMID: 37850688) Biol Blood Marrow Transplant. 2018 Mar;24(3):549-554. (PMID: 29247781) Biol Blood Marrow Transplant. 2014 May;20(5):724-9. (PMID: 24530426) Am J Hematol. 2018 Feb;93(2):246-253. (PMID: 29114918) Blood Rev. 2023 Nov;62:101093. (PMID: 37198064) Sci Rep. 2021 Jun 23;11(1):13125. (PMID: 34162921) Oncoimmunology. 2015 Mar 20;4(3):e974393. (PMID: 25949893) Biol Blood Marrow Transplant. 2020 Oct;26(10):1915-1922. (PMID: 32645444) Am J Hematol. 2020 Aug;95(8):892-899. (PMID: 32303111) Biol Blood Marrow Transplant. 2018 Apr;24(4):789-798. (PMID: 29355721) Clin Cancer Res. 2020 Nov 1;26(21):5549-5556. (PMID: 32409305) Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. (PMID: 24910379) J Clin Oncol. 2017 Sep 10;35(26):3002-3009. (PMID: 28644773) Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. (PMID: 30599208) Blood. 2015 Aug 20;126(8):1033-40. (PMID: 26130705) Leukemia. 2020 Oct;34(10):2766-2775. (PMID: 32393841) Blood. 2019 Sep 19;134(12):924-934. (PMID: 31292117) Transplant Cell Ther. 2022 Jan;28(1):20.e1-20.e10. (PMID: 34607074) Front Oncol. 2019 Nov 19;9:1217. (PMID: 31803612) Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. (PMID: 18489989) J Transl Med. 2015 May 07;13:145. (PMID: 25948100) Blood Cancer J. 2024 Feb 19;14(1):31. (PMID: 38374026) Bone Marrow Transplant. 2020 Mar;55(3):544-552. (PMID: 31541204) Leukemia. 2022 Jan;36(1):155-164. (PMID: 34312462) Stem Cell Investig. 2023 Apr 10;10:8. (PMID: 37064266) Transpl Int. 2019 Dec;32(12):1322-1332. (PMID: 31432532) Haematologica. 2022 Apr 01;107(4):844-856. (PMID: 34435482) Ann Hematol. 2022 Aug;101(8):1795-1802. (PMID: 35575911) Bone Marrow Transplant. 2023 Aug;58(8):855-862. (PMID: 37117266) Cytotherapy. 2020 Mar;22(3):158-165. (PMID: 32057614) J Immunol. 1998 May 15;160(10):4951-60. (PMID: 9590243) Blood Adv. 2019 Sep 10;3(17):2581-2585. (PMID: 31484635) Bone Marrow Transplant. 2022 Apr;57(4):532-537. (PMID: 35066570) Ann Hematol. 2020 Jun;99(6):1341-1350. (PMID: 32342134) Leukemia. 2019 Jan;33(1):230-239. (PMID: 29907809) J Hematol Oncol. 2023 Feb 13;16(1):10. (PMID: 36782226) Oncoimmunology. 2017 Sep 14;6(11):e1356152. (PMID: 29147612) Blood Adv. 2022 Sep 13;6(17):4994-5008. (PMID: 35819449) J Clin Invest. 2019 Mar 26;129(6):2357-2373. (PMID: 30913039) Blood. 2014 Sep 25;124(13):2131-41. (PMID: 25139358) Blood Adv. 2022 Jun 14;6(11):3378-3385. (PMID: 35143644) Blood. 2004 Feb 15;103(4):1417-24. (PMID: 14576061) iScience. 2023 Jan 31;26(3):106085. (PMID: 36843851) Am J Hematol. 2022 Aug;97(8):1065-1074. (PMID: 35696192) N Engl J Med. 2023 Jun 22;388(25):2338-2348. (PMID: 37342922) Blood Adv. 2021 Mar 9;5(5):1360-1368. (PMID: 33661299) Bone Marrow Transplant. 2018 Dec;53(12):1522-1531. (PMID: 29703966) Bone Marrow Transplant. 2019 Jan;54(1):99-122. (PMID: 29988061) J Immunol. 2019 Apr 1;202(7):2141-2152. (PMID: 30787107) |
| فهرسة مساهمة: | Keywords: HLA-haploidentical transplantation; HLA-matched transplantation; allogeneic hematopoietic cell transplantation (allo-HCT); graft-versus-tumor (GVT) effect; post-transplant cyclophosphamide (PTCy) |
| المشرفين على المادة: | 8N3DW7272P (Cyclophosphamide) 0 (Immunosuppressive Agents) |
| تواريخ الأحداث: | Date Created: 20240621 Date Completed: 20240621 Latest Revision: 20240626 |
| رمز التحديث: | 20240627 |
| مُعرف محوري في PubMed: | PMC11187280 |
| DOI: | 10.3389/fimmu.2024.1403936 |
| PMID: | 38903503 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!